● Human Research Ethics Committee grants Bod full ethics approval for Cannabis Phase I Clinical Trial
● Approval received in unprecedented time period with no additional information required –largely due to
quality of cannabis extract, counterparties involved, superior trial design and calibre of clinical trial team
● Bod’s counterparties include specialty pharmaceutical Company, iX Biopharma and Linnea SA, owned by
Schwabe and Ipsen
● Success in Clinical trials will leave Bod with a standardised, reproducible and patent protected cannabis
product which can be distributed or licenced to major pharmaceutical companies globally
● Key milestone for Bod –significant progress continues on pipeline of research activities
● Cannabis trial expected to commence in near term at a highly renowned centre in Melbourne, Victoria
Bod’s counterparties include leading, Singapore stock exchange listed company, iX Biopharma Limited (market capitalisation: $99.5m), who will be manufacturing the sublingual wafer delivered during the trial and Linnea SA, a leading Swiss manufacturer of botanical extracts and pharmaceutical ingredients. Linnea are a subsidiary of Ipsen and Schwarbe (market capitalisation: €0.9b), who are distinctly focused on pharmaceuticals and oncology
